INTRODUCTION
The lack of oral effectiveness of progesterone inspired the search during recent years for progestational compounds which would be orally active. A number of such compounds have been synthesized, tested in animals and are now widely used in menstrual irregularities, habitual, threatened abortion, cycle regulation, treatment of infertility and/or in combination with oestrogens as contraceptives. However, many of these substances in addition to their pro¬ gestational activity produce certain side-effects such as androgenicity, masculinization of female foetuses and adrenal atrophy. The desirability of an orally active progestin which would be free from these objectionable properties led to the synthesis of a series of derivatives of 17-methylprogesterone (Deghenghi & Gaudry, 1961;  Deghenghi, Revesz & Gaudry, 1963) and their testing as progestational agents. The biological activity of 6-methyl-6-dehydro-17-methylprogesterone, which appeared to be the most promising member of this series, forms the subject of this paper. It has the following structural formula: CH, * Generic name of 6-methyl-6-dehydro-17-methylprogesterone. Immature female rabbits were primed with a total dose of 15^g oestrone given over a period of 6 days. From the 7th to the 12th day of the experiment the test compound was given daily, subcutaneously (in 0-2 ml of sesame oil) or orally (in 2 ml of sesame oil). Twenty-four hours after the last dose was given the animals were killed and sections removed from the proximal, middle and distal portions of each uterine horn. Specimens were fixed in Bouin's solution, sectioned at 5 µ and stained with Harris's haematoxylin and eosin stain. The sections were evaluated according to McPhail's grading system.
Duration of action ofprogestational activity
The duration of effect of a single dose in the above test was determined by the method of Junkmann (1954) . Progesterone, 17-hydroxyprogesterone caproate and map were used as reference compounds.
Immature female rabbits were primed with oestrone as previously described. On the 7th day the compound was given in a single high dose subcutaneously. On the following days 0-025^g of oestrone was then given daily subcutaneously. Groups of five animals were killed 3, 7, 10, 13 Twenty-four-day-old female hooded rats were injected subcutaneously with 30 units of pmsg (pregnant mare serum gonadotrophin). Exactly 56 hr later, they were injected s.c. with 10 units of hcg (human chorionic gonadotrophin).
The rats were killed and autopsied 24 hr after the hcg was given. The number of ova expelled from the oviduct was counted under the low power of a light microscope (Rowlands, 1942 Anti-androgenie effects Some progestational agents have been reported to have strong anti-androgenic effects. The compounds were assayed for this activity in castrated rats as described by Lerner, Bianchi & Borman (1960) . Progesterone and map were the reference compounds.
Twenty-one-to 23-day-old male hooded rats were castrated. Beginning on the day of castration the test compound alone and in combination with testos¬ terone propionate (t.p.) was given subcutaneously daily for 7 days. The animals were killed the day after the last injection and the levator ani muscle, ventral prostate and the seminal vesicles were removed and weighed. Body weight increases were determined.
The effect of Medrogestone on the sex organs of intact male rats was also determined.
Biological activity of Medrogestone 477
Effect on the developingfoetus
The effect of Medrogestone on the genitalia and reproductive system of female offspring of mothers treated during pregnancy was determined as described by Revesz, Chappel & Gaudry (1960) . Changes in the genitalia and reproductive system of male offspring were determined by the method of Hamada, Neuman & Junkmann (1963) .
Test compounds were administered subcutaneously (in sesame oil), from the 15th to the 20th day of pregnancy, to female hooded rats of the Long-Evans strain. The pups were removed by Caesarean section on the 22nd day and were placed with foster mothers. On the day of birth the anogenital distance was measured and the pups weighed. Animals which survived to the 20th day were autopsied and the reproductive system examined.
Oestrogenic activity
This assay was performed with oestrone as the reference compound in a modified Allen & Doisy (1923) Llaurado (1961) . Anti-aldosterone properties were also examined.
Glycogen deposition test
Glycogen deposition in Medrogestone-treated animals was determined in fasted adrenalectomized rats as described by Olsen, Thayer & Kopp (1944) . Single injections of the test compound were given to one group of animals 7 hr before the liver was removed. In a second group of animals consecutive in¬ jections were administered 24 and 7 hr before the removal of the liver. Hydrocortisone alcohol was used as reference compound.
Anti-inflammatory properties
Cotton pellet granuloma test. A single dose of the test compound was applied to carragheenin-soaked pellet irritants which were implanted subcutaneously in 478 C. Revesz and C. I. Chappel adrenalectomized rats as described by Bush & Alexander (1960) . Hydro¬ cortisone was used as the reference compound.
Croton oil granuloma pouch test. Rats bearing a croton oil granuloma pouch were prepared by the method of Selye (1953) , and the test compound was injected directly into the pouch (Robert & Nezamis, 1957) . map and hydrocortisone were used as reference compounds. 
RESULTS

Progestational activity
The progestational activity of a daily oral dose of 0-01 to 0-1 mg of Medro¬ gestone and map were equal as shown in Daily dose (mgjrat) (Table 4) . When 10 mg was given orally, Medrogestone was slightly more active than map. Single subcutaneous doses of 5 to 10 mg of Medrogestone and map given at the time of ovariectomy were equally effective in maintaining pregnancy (Table 5 ). Progesterone showed the same effect but only at extremely high doses.
Ovulation inhibition
Medrogestone was effective in inhibiting ovulation in rats. The subcutaneous ed 50 of Medrogestone alone was found to be 1-5 mg (Tableó). The correspond¬ ing dose of norethynodrel was 3-1 mg. The addition of 17oc-ethinyl oestradiol-3-methylether (mestranol) to norethynodrel decreased the ed50 with sub¬ cutaneous administration to 0-25 mg. When given orally norethynodrel was more 480 C. Revesz and C. L Chappel effective than Medrogestone, the respective ed50 doses being 2-8 and 4-8 mg.
However, the addition of 10 /ig of Premarin decreased the oral ed50 of Medro¬ gestone to 2-1 mg and 20 µg of Premarin decreased the ed50 of Medrogestone to 1-2 mg. Medrogestone had marked anti-androgenic effects at daily s.c. doses of 0-5, 2-0 and 5-0 mg. The anti-androgenic effect was slightly less pronounced when Medrogestone was given orally at dose levels of 2-0 and 5-0 mg. map showed only slight anti-androgenic effects with a daily s.c. dose of 2-0 mg only on the prostatic weight. Table 10 shows the results in intact animals. At daily doses of 2-0 and 5-0 mg given subcutaneously there was a significant decrease in the weight of the ventral prostate, seminal vesicles and levator ani.
Effect on developingfoetuses
In female offspring of mothers given daily subcutaneous doses up to 10 mg of Medrogestone during pregnancy no changes were observed at birth in the anogenital distance nor was any masculinizing effect detectable at 20 days of 483 age. In contrast, the anogenital distance was increased at birth and the external and internal genitalia were masculinized at 20 days of age in female rats from mothers treated daily during pregnancy with subcutaneous doses of 0-5 mg of map. No masculinization occurred at daily subcutaneous doses up to 100 mg of progesterone.
In male offspring of mothers given up to 10 mg of Medrogestone during pregnancy no change in the anogenital distance was observed at birth. How¬ ever, as seen in Table 11 , hypospadias and cryptorchidism were observed in male offspring at 20 days of age. This anti-masculinizing effect was observed when 10 and 20 mg daily doses were given to the mother, while at a 5 mg-dose level (25 mg/kg) the males of only one litter out of seven were affected. At the 2-5 mg-dose levels of Medrogestone no changes were observed. (Table 12 ). Progesterone decreased the adrenal and thymus weights at extremely high doses, while map produced the same changes at low doses. The histological changes in the adrenals found with map were the same as those described by Logothetopoulos, Sharma & Kraicer (1961) .
Effect on water and electrolyte metabolism
In saline-loaded adrenalectomized animals, Medrogestone in s.c. doses of 2-0 and 3-0 mg did not produce definite changes in water and electrolyte excretion. At a dose of 4-0 mg, however, it showed some tendency to reduce 484 C. Revesz and C. L Chappel urine volume and electrolyte output. In intact rats, repeated daily injections of 1-0 mg of Medrogestone caused a small but significant increase in the total sodium and potassium excretion. In adrenalectomized saline-loaded rats given ¿//-aldosterone acetate, Medro¬ gestone showed some anti-aldosterone properties at the 2-0 mg dose level.
Glycogen deposition test
Medrogestone did not increase liver glycogenesis at total doses of 1-0 and 2-0 mg s.c. 
